Pd18-11 Delayed Partial Nephrectomy Following Complete Response to Immunotherapy: Feasibility and Results (Uroccr N°157)

You have accessJournal of UrologyKidney Cancer: Advanced (Including Drug Therapy) II (PD18)1 May 2024PD18-11 DELAYED PARTIAL NEPHRECTOMY FOLLOWING COMPLETE RESPONSE TO IMMUNOTHERAPY: FEASIBILITY AND RESULTS (UROCCR N°157) Gaëlle Margue, Bastien Parier, Laurence Albiges, Clément Klein, Géraldine Pignot, Gwenaëlle Gravis, Pierre Bigot, Nathalie Baize, Alexandre Ingels, Charlotte Joly, François Audenet, Yann Vano, Thibaut Waeckel, Romain Levard, Marine Gross-Goupil, and Jean-Christophe Bernhard Gaëlle MargueGaëlle Margue , Bastien ParierBastien Parier , Laurence AlbigesLaurence Albiges , Clément KleinClément Klein , Géraldine PignotGéraldine Pignot , Gwenaëlle GravisGwenaëlle Gravis , Pierre BigotPierre Bigot , Nathalie BaizeNathalie Baize , Alexandre IngelsAlexandre Ingels , Charlotte JolyCharlotte Joly , François AudenetFrançois Audenet , Yann VanoYann Vano , Thibaut WaeckelThibaut Waeckel , Romain LevardRomain Levard , Marine Gross-GoupilMarine Gross-Goupil , and Jean-Christophe BernhardJean-Christophe Bernhard View All Author Informationhttps://doi.org/10.1097/01.JU.0001008596.32809.c5.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Complete responses to immunotherapy (IO) in metastatic kidney cancer have led to a renewed interest in primary site surgery. The prolonged survival of these patients has prompted consideration for nephron-sparing surgery when it is technically feasible. However, in view of the surgical difficulties reported in the literature, it is essential to assess the feasibility as well as the functional and oncological results of partial nephrectomy (PN) following IO. METHODS: Using the UroCCR database (CNIL DR 2013-206; NCT03293563), we conducted a multicentric retrospective study including all metastatic patients who underwent PN after a complete response to IO on metastatic sites. We assessed intraoperative difficulties, morbidity, renal function, positive margin rate, and oncological outcomes. RESULTS: Between January 2019 and September 2023, 13 patients underwent PN following IO. Population characteristics and surgical outcomes are described in Table 1. After surgery, IO was not reintroduced in ten patients (77%), one patient continued treatment for 2 months and two patient was still on treatment at last follow-up (no recurrence). Median GFR at 3 months was 84.7 66.6–95.2 mL/min/1.73 m2 with no significant difference from preoperative GFR. Median follow-up was 8.4 3.0–21.1 months and overall survival at last follow-up was 90%. Median treatment-free survival was 12.9 8.0–30.9 months and recurrence-free survival at 12 months was 84.6%. CONCLUSIONS: This first series of delayed PN following IO confirms the feasibility of the procedure with good functional and oncological results leading to prolonged remissions. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e437 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Gaëlle Margue More articles by this author Bastien Parier More articles by this author Laurence Albiges More articles by this author Clément Klein More articles by this author Géraldine Pignot More articles by this author Gwenaëlle Gravis More articles by this author Pierre Bigot More articles by this author Nathalie Baize More articles by this author Alexandre Ingels More articles by this author Charlotte Joly More articles by this author François Audenet More articles by this author Yann Vano More articles by this author Thibaut Waeckel More articles by this author Romain Levard More articles by this author Marine Gross-Goupil More articles by this author Jean-Christophe Bernhard More articles by this author Expand All Advertisement PDF downloadLoading ...